Regarding ICI combination therapies, a phase II trial of the poly ADP ribose polymerase inhibitor (PARPi) talazoparib combined with avelumab (PD-L1 antibody) in genomically defined metastatic kidney cancer reported an ORR of 0% in a cohort of eight patients that included four FH-deficient RCC and one SDH-deficient RCC [78]. Here, FH is linked to renal cell adenocarcinoma.